Cataract Therapeutics - Pipeline Review 2018, In-Depth Study on Therapeutics Development, Assessment & Growth

Cataract is the clouding of eye lens and it can occur in either one or both the eyes. Cataract is generally more common among people over 80 years of age. According to the National Eye Institute, more than half of the Americans suffer from cataract. Eye lens is transparent and light sensitive and is located at the back of the eye. It helps to focus light rays on retina which aids in the formation of clear image. Images at retina are converted into optic signals that are then communicated to the brain. Eye lens is made up of protein and water, but as a person grows old, the protein of the lens clump together and starts to form a cloud which continues to grow, time making it harder for patients to see. Cloud formation in eye lens is the characteristic feature of cataract. In people affected by cataract, colour of eye lens also changes to brownish, adding a brownish tint to their vision.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cataract-therapeutics-pipeline-analysis/report-sample

Considerable growth in therapeutic pipeline of cataract is expected in the future which could be attributed primarily to the increasing prevalence of cataract. According to researchers, smoking and diabetes are considered to be the major causes of cataract disease. Consumption of unhygienic crops and fruits, unhealthy lifestyle and rising level of pollutants in the environment are some of other important factors responsible for increasing incidence of cataract disease.

In September 2016, Johnson & Johnson Pharmaceutical Ltd. entered into an agreement with Abbott Medical Optics Inc. (AMO) to acquire for the wholesome amount of $4.325 billion. AMO’s reported sales were around $1.1 billion for the year 2015. The acquisition also included accession of ophthalmic products in three business segments such as, cataract surgery, laser refractive surgery and consumer eye health. In March 2016, Acucela Inc. and YouHealth Eyetech Inc. signed an agreement of license on lanosterol technology for the non-surgical pharmacologic treatment of cataracts.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cataract-therapeutics-pipeline-analysis

Some of the companies having a pipeline of cataract therapeutics include, Allergan plc, Genentech, Inc., Aqumen Biopharmaceuticals, N.A., Reata Pharmaceuticals, Inc. Bausch & Lomb Incorporated, Omeros Corporation, Chakshu Research, Inc., Santen Pharmaceutical Co., Ltd., Eyegate Pharmaceuticals, Inc., Icon Bioscience Inc., Othera Pharmaceuticals Inc., Xigen SA, Regeneron Pharmaceuticals Inc., ESBATech AG, Valeant Pharmaceuticals International, Inc., Ivantis, Inc., Eyetech Pharmaceuticals Inc., Ocular Therapeutix, Inc., Merck Sharp & Dohme Corp., Dompé Farmaceutici S.p.A, Sirion Therapeutics, Inc., Croma-Pharma GmbH, Kala Pharmaceuticals, Inc. and Amgen plc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.